Q32 Bio (QTTB) Other Non-Current Assets (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Other Non-Current Assets of $325000.0 for Q1 2026, down 49.77% year-over-year from $647000.0 in Q1 2025, and down 49.77% quarter-over-quarter from $647000.0 in Q4 2025.
Q32 Bio (QTTB) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Q32 Bio's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $325000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 49.77% year-over-year to $325000.0; the TTM figure through Mar 2026 stood at $325000.0 (down 49.77% YoY), while the FY2025 annual figure was $647000.0, up 457.76% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $325000.0, down from $647000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.6 million in Q4 2023, with the low at $12000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $647000.0 (2024), against an average of $966818.2.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets plunged 97.95% in 2024, then surged 4650.0% in 2025.
- Q32 Bio's Other Non-Current Assets stood at $276000.0 in 2022, then surged by 1946.01% to $5.6 million in 2023, then slumped by 97.95% to $116000.0 in 2024, then soared by 457.76% to $647000.0 in 2025, then slumped by 49.77% to $325000.0 in 2026.
- Business Quant data shows QTTB's Other Non-Current Assets at $325000.0 in Q1 2026, $647000.0 in Q4 2025, and $647000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 647,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 647,000.00 |
| Mar 31, 2026 | 325,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | 647,000.00 |
| Jun 30, 2025 | 570,000.00 |
| Mar 31, 2025 | 647,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 647,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 1.95 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Sep 30, 2020 | 1.27 Mn |
| Jun 30, 2020 | 1.27 Mn |
| Mar 31, 2020 | 1.27 Mn |